Senores Pharmaceuticals reported robust financial and operational growth in the third quarter of the 2025‑26 financial year, driven by strong performance in its regulated markets and expanding global footprint.
The company posted consolidated revenue of ₹175 crore in Q3 FY26, marking a 64 per cent increase compared with the same period last year. Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose sharply, and profit after tax more than doubled year‑on‑year, reflecting a broad‑based improvement across business segments.
Revenue from regulated markets, which include the United States, Canada and other high‑compliance regions, accounted for the majority of growth, rising more than 60 per cent in the quarter. Senores has continued to expand its product portfolio in these markets, increasing the number of approved Abbreviated New Drug Applications (ANDAs) and advancing a pipeline of additional filings.
Emerging markets also delivered their highest‑ever quarterly revenue and EBITDA, with broader geographic reach and an expanding catalogue of registered products contributing to stronger performance. In its India branded generics business, the company saw a substantial uplift in sales, with revenue growing several‑fold year‑on‑year as products gained traction within multi‑specialty hospital networks.
Across the first nine months of FY26, total consolidated revenue reached ₹474 crore, up around 65 per cent, with corresponding increases in EBITDA and profit after tax. Operating cash flow improved considerably, supported by stronger earnings and tighter working capital management.
Senores’ strategic expansion of its regulated markets portfolio and broader global operations underpinned the quarter’s results. The company maintains a diversified business mix spanning regulated markets, emerging markets and domestic branded generics, with ongoing product launches planned to sustain growth momentum.
